IL133626A0 - Treatment of insulin resistance with growth hormone secretagogues - Google Patents

Treatment of insulin resistance with growth hormone secretagogues

Info

Publication number
IL133626A0
IL133626A0 IL13362698A IL13362698A IL133626A0 IL 133626 A0 IL133626 A0 IL 133626A0 IL 13362698 A IL13362698 A IL 13362698A IL 13362698 A IL13362698 A IL 13362698A IL 133626 A0 IL133626 A0 IL 133626A0
Authority
IL
Israel
Prior art keywords
treatment
growth hormone
insulin resistance
hormone secretagogues
secretagogues
Prior art date
Application number
IL13362698A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Priority to IL15646598A priority Critical patent/IL156465A/en
Priority to IL15411598A priority patent/IL154115A0/xx
Priority to IL15411698A priority patent/IL154116A0/xx
Priority to IL15411298A priority patent/IL154112A0/xx
Priority to IL15411198A priority patent/IL154111A0/xx
Priority to IL15411498A priority patent/IL154114A0/xx
Publication of IL133626A0 publication Critical patent/IL133626A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13362698A 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues IL133626A0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IL15646598A IL156465A (en) 1997-06-25 1998-06-05 Scrotagogens of growth hormone for use in the treatment of sleep disorders
IL15411598A IL154115A0 (en) 1997-06-25 1998-06-05 Process for the preparation of growth hormone secretagogues
IL15411698A IL154116A0 (en) 1997-06-25 1998-06-05 Sythesis of intermediates for the preparation of growth hormone secretagogues
IL15411298A IL154112A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15411198A IL154111A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15411498A IL154114A0 (en) 1997-06-25 1998-06-05 Composition for use as a medicament for increasing levels of endogeneous growth hormone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (1)

Publication Number Publication Date
IL133626A0 true IL133626A0 (en) 2001-04-30

Family

ID=21967444

Family Applications (7)

Application Number Title Priority Date Filing Date
IL13362698A IL133626A0 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues
IL15411198A IL154111A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15411598A IL154115A0 (en) 1997-06-25 1998-06-05 Process for the preparation of growth hormone secretagogues
IL15411298A IL154112A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15646598A IL156465A (en) 1997-06-25 1998-06-05 Scrotagogens of growth hormone for use in the treatment of sleep disorders
IL15411498A IL154114A0 (en) 1997-06-25 1998-06-05 Composition for use as a medicament for increasing levels of endogeneous growth hormone
IL15411698A IL154116A0 (en) 1997-06-25 1998-06-05 Sythesis of intermediates for the preparation of growth hormone secretagogues

Family Applications After (6)

Application Number Title Priority Date Filing Date
IL15411198A IL154111A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15411598A IL154115A0 (en) 1997-06-25 1998-06-05 Process for the preparation of growth hormone secretagogues
IL15411298A IL154112A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15646598A IL156465A (en) 1997-06-25 1998-06-05 Scrotagogens of growth hormone for use in the treatment of sleep disorders
IL15411498A IL154114A0 (en) 1997-06-25 1998-06-05 Composition for use as a medicament for increasing levels of endogeneous growth hormone
IL15411698A IL154116A0 (en) 1997-06-25 1998-06-05 Sythesis of intermediates for the preparation of growth hormone secretagogues

Country Status (40)

Country Link
US (3) US6448263B1 (enExample)
EP (1) EP1000085B1 (enExample)
JP (2) JP2000514099A (enExample)
KR (1) KR20010014224A (enExample)
CN (2) CN1152049C (enExample)
AP (1) AP1145A (enExample)
AR (1) AR012256A1 (enExample)
AT (1) ATE305477T1 (enExample)
AU (1) AU747510B2 (enExample)
BG (1) BG104008A (enExample)
BR (1) BR9810477A (enExample)
CA (1) CA2294464A1 (enExample)
CO (1) CO4950621A1 (enExample)
DE (1) DE69831745T2 (enExample)
DZ (1) DZ2539A1 (enExample)
EA (1) EA002089B1 (enExample)
EG (1) EG21712A (enExample)
ES (1) ES2248899T3 (enExample)
HN (1) HN1998000088A (enExample)
HR (1) HRP980361A2 (enExample)
HU (1) HUP0001922A3 (enExample)
ID (1) ID24345A (enExample)
IL (7) IL133626A0 (enExample)
IN (1) IN189724B (enExample)
IS (1) IS5275A (enExample)
MA (1) MA24581A1 (enExample)
NO (1) NO996205L (enExample)
NZ (1) NZ500655A (enExample)
OA (1) OA11242A (enExample)
PA (1) PA8452601A1 (enExample)
PE (1) PE105399A1 (enExample)
PL (1) PL337659A1 (enExample)
SK (1) SK175699A3 (enExample)
TN (1) TNSN98113A1 (enExample)
TR (1) TR199903257T2 (enExample)
TW (1) TW553943B (enExample)
UA (1) UA64751C2 (enExample)
WO (1) WO1998058949A1 (enExample)
YU (1) YU70199A (enExample)
ZA (1) ZA985546B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
KR20050071498A (ko) * 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 성장 호르몬 방출 호르몬 유사체
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
MX2007007396A (es) * 2004-12-21 2007-08-14 Hercules Inc Resinas cationicas reactivas para usarse como agentes de resistencia secos y humedos en sistemas de fabricacion de papel que contienen iones sulfito.
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US9371297B2 (en) 2007-02-09 2016-06-21 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
CA2910123C (en) * 2013-05-28 2021-11-02 Raqualia Pharma Inc. Polymorph form of 2-amino-n-[2-(3a-(r)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro­pyrazolo[4,3-c]pyridin-5-yl)-1-(r)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide l-tartrate
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CN106459147B (zh) * 2014-08-05 2021-08-06 拉夸里亚创药株式会社 作为生长激素释放肽受体激动剂的丝氨酸衍生物
TW201625613A (zh) 2014-10-31 2016-07-16 拉夸里亞創藥股份有限公司 作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2024217441A1 (zh) * 2023-04-21 2024-10-24 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3190802A (en) 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
JPH08503213A (ja) 1992-11-06 1996-04-09 メルク エンド カンパニー インコーポレーテッド 成長ホルモンの放出を促進する置換ジペプチド同族体
CZ151495A3 (en) 1992-12-11 1995-12-13 Merck & Co Inc Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
BR9408019A (pt) 1993-11-09 1997-08-26 Merck & Co Inc Composto composição util para aumentar a produção endógena ou a liberaçao de hormonio do crescimento em ser humano ou um animal e para o tratamento da osteoporose processos para aumentar os niveis de hormônio do crescimento em um ser humano ou um animal e a eficácia de alimentação promover o crescimento aumentar a produçao de leite e melhorar a qualidade da carcaça de gado para tratar ou previnir uma condição selecionada para tratar osteoporose e para preparar um composto
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
AU715856B2 (en) 1995-12-22 2000-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1998058947A1 (en) * 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)

Also Published As

Publication number Publication date
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
PL337659A1 (en) 2000-08-28
WO1998058949A1 (en) 1998-12-30
CN1530107A (zh) 2004-09-22
ATE305477T1 (de) 2005-10-15
ES2248899T3 (es) 2006-03-16
NO996205D0 (no) 1999-12-15
JP2000514099A (ja) 2000-10-24
US6867202B1 (en) 2005-03-15
ID24345A (id) 2000-07-13
EG21712A (en) 2002-02-27
US6630487B2 (en) 2003-10-07
IS5275A (is) 1999-11-26
JP2005097261A (ja) 2005-04-14
IL154114A0 (en) 2003-07-31
EA199901075A1 (ru) 2000-08-28
IL154115A0 (en) 2003-07-31
CO4950621A1 (es) 2000-09-01
EP1000085B1 (en) 2005-09-28
ZA985546B (en) 2000-01-10
SK175699A3 (en) 2001-04-09
NZ500655A (en) 2002-02-01
TNSN98113A1 (fr) 2005-03-15
KR20010014224A (ko) 2001-02-26
HUP0001922A3 (en) 2001-02-28
EA002089B1 (ru) 2001-12-24
TW553943B (en) 2003-09-21
IL156465A0 (en) 2004-01-04
AP9801267A0 (en) 1998-06-30
TR199903257T2 (xx) 2000-12-21
AP1145A (en) 2003-02-14
EP1000085A1 (en) 2000-05-17
DZ2539A1 (fr) 2003-02-08
DE69831745D1 (de) 2006-02-09
MA24581A1 (fr) 1998-12-31
PA8452601A1 (es) 2000-05-24
BR9810477A (pt) 2007-05-22
PE105399A1 (es) 1999-11-04
OA11242A (en) 2003-07-23
HRP980361A2 (en) 1999-02-28
IL156465A (en) 2004-07-25
HN1998000088A (es) 1999-01-08
HK1028051A1 (en) 2001-02-02
IN189724B (enExample) 2003-04-19
IL154116A0 (en) 2003-07-31
UA64751C2 (uk) 2004-03-15
US20030100561A1 (en) 2003-05-29
YU70199A (sh) 2003-01-31
BG104008A (en) 2000-07-31
CN1259140A (zh) 2000-07-05
AU7445698A (en) 1999-01-04
DE69831745T2 (de) 2006-08-31
CA2294464A1 (en) 1998-12-30
IL154111A0 (en) 2003-07-31
AU747510B2 (en) 2002-05-16
NO996205L (no) 1999-12-15
US6448263B1 (en) 2002-09-10
JP3742643B2 (ja) 2006-02-08
CN1152049C (zh) 2004-06-02
AR012256A1 (es) 2000-09-27

Similar Documents

Publication Publication Date Title
IL156465A0 (en) Treatment of insulin resistance with growth hormone secretagogues
EP0741578A4 (en) HUMAN GROWTH HORMONE
IL128128A (en) Composition comprising insulin and insulin-like growth factor (i-igf)
HU9601013D0 (en) Combination of bisphosphonates and growth hormone secretagogues
HUP9802580A3 (en) Compounds with growth hormone releasing properties
EP1056514A4 (en) ENDOLUMINAL IMPLANT WITH THERAPEUTIC AND DIAGNOSTIC CAPABILITIES
EP0956057A4 (en) INFUSION DEVICE WITH DISPOSABLE ELEMENTS
ZA987383B (en) Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) Growth hormone secretagogues.
EP0688570A3 (de) Insulinspritze
HUP9802821A3 (en) Compounds with growth hormone releasing properties
EP0709395A3 (en) Preparation of Stable Insulin Analog Crystals
HU9904384D0 (en) Process and intermediates for growth hormone secretagogues
IL144350A0 (en) Growth hormone secretagogues
PL343123A1 (en) Treatment of diabetes with rosiglitazone and insulin
ZA961007B (en) Compounds with growth hormone releasing properties
PL336579A1 (en) Treatment of diseases associated with cytokinins
EP1126854A4 (en) BENZOAZEPINES AND THEIR ANALOGS AS MEANS THAT PROMOTE THE SECRETION OF THE GROWTH HORMONE
HUP9904175A3 (en) Human growth gene and short stature gene region
AU7609298A (en) Treatment of heart failure with growth hormone
SI1007085T1 (en) Use of growth hormone in compositions for treating insulin resistance in the heart
SI0935469T1 (en) Use of growth hormone
AUPP582198A0 (en) Modified human growth hormone
GB9611002D0 (en) Enhancement of sleep with a growth hormone secreragogue
GB9614941D0 (en) Treatment of mood disorders with a growth hormone secretagogue